Alpelisib can also bind to wild-type PIK3CA (PI3K protein), which results in pronounced off-target effects, such as hyperglycaemia [4]; however, inavolisib and RLY-2608 (emerging drug heading into Phase III trials) specifically target mutant PI3K. The gene discussed is PIK3CA; the disease is Hyperglycemia.